Generic and innovative drugs markets in Central and Eastern Europe 2009 provides a study analysis of the eight generic and innovative drugs markets in the CEE:
- Bulgaria,
- Czech Republic,
- Hungary,
- Poland,
- Romania,
- Russia,
- Slovakia,
- Ukraine.
The report focuses on a comparative analysis of Central and Eastern European policies towards the use of generic and innovative drug applications and covers such important areas like the legal framework, counterfeit products and reimbursement and pricing policies. The report delivers key data on the total size of the CEE generic and innovative drugs market, the market share for each country in the region and development forecasts up to 2011. In addition, Generic and innovative drugs markets in Central and Eastern Europe 2009 Comparative analysis, reimbursement policies and development forecasts 2009-2011 provides details on patent and data exclusivity protection trends and facts in the countries analysed as well as scale of counterfeiting in each of the countries.
List of graphs
- Value (€ bn) and y-o-y growth of the generics drug market in Central and Eastern Europe, 2007-2011
- Value (€ bn) and y-o-y growth of the innovative drug market in Central and Eastern Europe, 2007-2011
- CAGR for generics drug markets in the countries analysed, 2009-2011
- CAGR for innovative drug markets in the countries analysed, 2009-2011
- Percentage of top 20 global companies sales exposed to generic competition, before and after 2012
- Number of molecules available to patients at reference date in CEE countries in comparison with the countries with the highest scores, 2007
- The proportion of total sales of cancer drugs in selected CEE countries analysed, by date of launch, 2007
- Value (€ bn) and y-o-y growth of the generics drug market in Central and Eastern Europe, 2007-2011
- Value (€ bn) and y-o-y growth of the innovative drug market in Central and Eastern Europe, 2007-2011
- Share of generic and innovative drugs as a proportion of the overall pharmaceutical market of Central and Eastern Europe, 2008-2011
- Share of generic and innovative drugs as a proportion of the overall pharmaceutical market in the countries analysed, 2008
- Market value ($ m) of generic and innovative medicines in Russia, 2005-2008
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Russia, by value, 2007
- Share of high-tech pharmaceutical substances as proportion of total market value in Russia, 2009
- Share of foreign innovative substances as a proportion of reimbursement and hospital purchases in Russia, by value, 2007
- Share of foreign innovative substances as a proportion of reimbursement and hospital purchases in Russia, by volume, 2007
- Market value (€ m) and y-o-y growth of the Russian generics drug market, 2007-2011
- Market value (€ m) and y-o-y growth of the Russian innovative drug market, 2007-2011
- Definitions of “innovative drug” provided by pharmacists in Russia, 2008
- Definitions of “innovative drug” provided by doctors in Russia, 2008
- Definitions of “branded generic” provided by pharmacists in Russia, 2008
- Definitions of “branded generic” provided by doctors in Russia, 2008
- Opinions of Russian doctors and pharmacists on innovative drugs, 2008
- Incidence of often prescribing innovative and generic drugs among Russian cardiologists and physicians, 2008
- Which kinds of drugs are most in demand at your pharmacy?, Russia, 2008
- Market value (PLN m) of generic and innovative medicines in Poland, 2004-2007
- Market volume (million of units) of generic and innovative medicines in Poland, 2004-2007
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by value, Q3 2007 - Q3 2008
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by volume, Q3 2007 - Q3 2008
- Share of generic and innovative drugs as a proportion of Rx pharmaceutical market in Poland, by value, 2004-2007
- Share of generic and innovative drugs as a proportion of Rx pharmaceutical market in Poland, by volume, 2004-2007
- Share of generic and innovative drugs as a proportion of reimbursed drug market in Poland, by value, Q1 2002-Q3 2008
- Market value (€ m) and y-o-y growth of the Polish generics drug market, 2007-2011
- Market value (€ m) and y-o-y growth of the Polish innovative drug market, 2007-2011
- Doctors informing Polish patients about cheaper equivalents of expensive drugs, 2001, 2003, 2005 and 2007
- Poles’ opinions on Polish equivalents of foreign drugs, 2001, 2003, 2005 and 2007
- Respondents’ opinions about generic drugs in Poland and other European countries, 2008
- Attitudes of Poles toward innovative drugs and treatment, 2008
- Ethical forms of meetings with pharmaceutical representatives in Poland (% of respondents), 2008
- The best form of contact with a pharmaceutical representative in Poland (% of respondents), 2009
- Proposed reduction in prices of medicines in the Czech Republic, 2009
- Market value (CZK bn) of generic and innovative medicines in the Czech Republic, 2004-2008
- Sales of orphan drugs in the Czech Republic, by value (CZK m), 2005-H1 2009
- Sales of orphan drugs in the Czech Republic, by volume, 2005-H1 2009
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in the Czech Republic, by value, 2001-2007
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in the Czech Republic, by volume, 2001-2007
- Market value (€ m) and y-o-y growth of the Czech generics drug market, 2004-2011
- Market value (€ m) and y-o-y growth of the Czech innovative drug market, 2004-2011
- Estimated share of generic and innovative drugs as a proportion of overall pharmaceutical market in Romania, by value, 2008
- Estimated share of generic and innovative drugs as a proportion of overall pharmaceutical market in Romania, by volume, H1 2009
- Market value (€ m) and y-o-y change of the Romanian generics drug market, 2007-2011
- Market value (€ m) and y-o-y change of the Romanian innovative drug market, 2007-2011
- Estimated share of generic and innovative drugs as a proportion of pharmaceutical market in Hungary, by value, 2008
- Respondent’s opinion about generic drugs in Hungary and other European countries, 2006
- Market value (UAH bn) and number of packages sold (m) of generic and innovative medicines in Ukraine, January-July 2009
- Average price of generic and innovative medicines in the Ukrainian retail market (UAH), January 2006-August 2008
- Share of generic and innovative drugs as a proportion of retail pharmaceutical market in Ukraine, by value, January 2007-July 2009
- Share of generic and innovative drugs as a proportion of retail pharmaceutical market in Ukraine, by volume, January 2007-July 2009
- Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by value, H1 2007 and H1 2008
- Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by volume, H1 2007 and H1 2008
- Market value (€ m) and y-o-y growth of the Ukrainian generics drug market, 2007-2011
- Market value (€ m) and y-o-y growth of the Ukrainian innovative drug market, 2007-2011
- Doctors’ knowledge of the prices of Rx medicines which they prescribe in Ukraine, 2009
- Price breakdown of generic and original drug market in Ukraine, in the opinion of doctors , 2009
- Sources of information on drug prices for physicians in Ukraine, 2009
- Estimated market value (SKK m) of generic and innovative medicines in Slovakia, 2007-2008
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Slovakia, by value, 2008
- Market value (€ m) and y-o-y growth of the Slovak generics drug market, 2005-2011
- Market value (€ m) and y-o-y growth of the Slovak innovative drug market, 2005-2011
- Understanding of the term “generic medicinal product” in Slovakia, 2007
- Attitudes of patients toward the use of generic drugs in Slovakia, 2007
- Attitudes of patients toward generic substitutes in Slovakia, 2007
- Market value (BGN m) and number of packages sold (m) of generic and innovative medicines in Bulgaria, 2007-2008
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Bulgaria, by value and volume, by INN, 2008
- Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Bulgaria, by value, by company image, 2006-2008
- Market value (€ m) and y-o-y growth of the Bulgarian generics drug market, 2007-2011
- Market value (€ m) and y-o-y growth of the Bulgarian innovative drug market, 2007-2011
- Amount of money patients had to spend on drugs used in hospital treatment in Bulgaria, 2008
- Source of funding of drugs used in home treatment in Bulgaria, 2008
- Satisfaction with state drug policy in Bulgaria, 2008
- Opinions about state drug policy in Bulgaria, 2008
- Doctors’ opinions on generic and innovative drugs in Bulgaria, 2007
- The difference between the cost of an imported drug and its final consumer price in Russia, Q2 2009
- Average retail markup for drugs in selected regions of Russia, Q1 2009
- Expenses within the Federal Reimbursement Programme in Russia (RUB bn), 2008-2009
- The share of local and imported drugs as a proportion of the Russian pharmaceutical market, by value, H1 2008 and H1 2009
- Pricing and reimbursement process in Russia, 2009
- Average pharmacy margin for non-reimbursed products in Poland, January 2008-June 2009
- Price build-up of reimbursed medicines in Poland, pharmacy market, 2009
- Distribution of medicines in the Czech Republic in accordance with price of medicine, by volume and by value, Q2 2009
- Share of the cheapest and the most expensive drugs as a proportion of the overall Rx market in Romania, 2008 and Q2 2009
- Gross average retail markup for drugs in Romania, 2009
- Average retail markup for generic and innovative drugs in Ukraine, January 2006-August 2008
- Example calculation of the maximum price of an Rx medicine in Slovakia, 2009
- AstraZeneca spending on research and development ($ m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
- Bayer HealthCare sales structure, by division, 2008
- Bayer HealthCare spending on research and development (€ m), y-o-y change and its share as a proportion of the company’s net sales, 2004-2008
- GlaxoSmithKline spending on research and development (£ m), y-o-y change and its share as a proportion of the company’s turnover, 2001-2008
- Novartis group sales structure, 2008
- Novartis Pharmaceuticals spending on research and development ($ m), y-o-y increase and its share as a proportion of the company’s net sales, 2004-2008
- Pfizer spending on research and development ($ m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
- Roche sales structure, by division, 2008
- Sales of key Roche products in Romania, H1 2009
- Roche Pharmaceuticals spending on research and development (CHF m), y-o-y increase and its share as a proportion of the company’s sales, 2004-2008
- Sanofi-Aventis ownership structure, June 2009
- Sanofi-Aventis sales structure in Russia, 2008
- Sanofi-Aventis spending on research and development (€ m), y-o-y increase and its share as a proportion of the company’s net sales, 2004-2008
- Sales of key Servier products in Romania, H1 2009
- Actavis sales revenues structure, by region, 2008
- Antibiotice ownership structure, September 2009
- Revenues (RON m) and y-o-y change of Antibiotice, 2002-2008
- Dr. Reddy’s ownership structure, March 2009
- Sales revenues ($ m) from generic drug sales and y-o-y growth of Dr. Reddy’s in Russia, FY 05 - FY 09
- Dr. Reddy’s spending on research and development (RS m), y-o-y change and its share in company’s revenues, FY 01-09
- Egis ownership structure, June 2009
- Egis sales in CEE countries, Q1-Q3 2008/2009
- Sales revenues ($ m) and y-o-y change of Egis in the CEE countries analysed, Q1-Q3 2008/2009
- Egis spending on research and development (HUF m), y-o-y increase and its share in company’s net sales, FY 2000/2001-2008/2009
- Gedeon Richter ownership structure, June 2009
- Gedeon Richter sales in CEE countries, H1 2009
- Sales turnover (€ m) of Gedeon Richter in the CEE countries analysed, 2008 and H1 2009
- Share of original drugs as a proportion of Gedeon Richter’s total sales, 2008
- Share of original drugs as a proportion of Gedeon Richter’s total sales, 2000-2008
- Gedeon Richter spending on research and development (HUF m), y-o-y increase and its share as a proportion of the company’s sales, 2000-H1 2009
- Krka ownership structure, June 2009
- Krka sales in CEE countries, H1 2009
- Sales revenues (€ m) and y-o-y change of Krka in the CEE countries analysed, H1 2009
- Number of new marketing authorisations obtained by Krka in Central European region, 2004-2008
- Krka spending on research and development (€ m), y-o-y increase and its share in company’s sales revenues, 2003-H1 2009
- Pharmstandard ownership structure, H1 2009
- Sales value (RUB bn) and y-o-y growth of Pharmstandard in Russia, 2004-H1 2009
- Pharmstandard sales structure, by branded and non-branded OTC and Rx drugs, H1 2009
- Ranbaxy ownership structure, 2008
- Sales value ($ m) and y-o-y change of Ranbaxy on its key CEE markets, 2008 and H1 2009
- Sales value ($ m) and y-o-y change of Ranbaxy in Romania, 2004-H1 2009
- Ranbaxy spending on research and development (RS m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
- Sandoz sales growth on selected CEE markets, 2007
- Sanzoz’s spending on research and development ($ m), y-o-y increase and its share in company’s net sales, 2005-2008
- Stada sales in CEE countries, H1 2009
- Sales value (€ m) of Stada in the analysed CEE countries, 2008 and H1 2009
- Sales (€ m) of generic and branded drugs of Stada in selected CEE countries analysed, 2008
- Sales (€ m) of generic and branded drugs of Stada in the CEE countries analysed, H1 2009
- Stada spending on research and development (€ m), y-o-y increase and its share in company’s sales, 2001-2008
- Teva global sales, by region, Q2 2009
- Sales revenues (HRK m) and y-o-y change of Pliva, 2006-H1 2009
- Teva’s spending on research and development ($ m), y-o-y increase and its share as a proportion of the company’s revenues, 2001-2008
- Zentiva sales in CEE countries, 2008
- Net pharmaceutical sales (CZK m) and y-o-y change of Zentiva in the CEE countries analysed, 2008
- Zentiva’s spending on research and development (CZK m), y-o-y change and its share as a proportion of the company’s net sales, 2003-2008
List of tables
- Annual average exchange rates used for this report (euro to national currency unit), 2006-2008
- Optimal drug prices in Ukraine, according to the doctors, 2009
- Top 10 best selling drugs on the retail pharmaceutical market in Russia, generic and innovative, 2008
- Top 10 best selling drugs in the reimbursement subdivision in Russia, generic and innovative, 2008
- Top 10 best selling drugs on the hospital pharmaceutical market in Russia, generic and innovative, 2008
- Top 10 best selling Rx drugs in Poland, generic and innovative, 2008
- Top 10 best selling drug substances in the Czech Republic, generic and innovative, H1 2009
- The most frequently reimbursed medicinal substances in the category of the cheapest medicines in the Czech Republic, Q2 2009
- The best selling drugs in the category of the most expensive medicines in the Czech Republic, Q2 2009
- Sales volume of selected best selling medicines in Romania (million units), generic and innovative, H1 2009
- Top 10 best selling drugs in Romania, generic and innovative, H1 2009
- Top 10 best selling drugs in Hungary, generic and innovative, 2008
- Top 10 best selling drugs in Ukraine, generic and innovative, 2008
- Comparison of drug patent expiry and data exclusivity periods (years) in the Central and Eastern European countries analysed, 2009
- Examples of patent/trademark infringement cases in Central and Eastern Europe
- Official retail margins for reimbursed drugs in Poland, 2009
- Official margins for reimbursed drugs in the Czech Republic, 2009
- Official wholesale margins for drugs in Romania, 2009
- Official retail margins and gross margins for drugs in the Romania, 2009
- Changes to reimbursement lists in Romania, July 2008
- Solidarity fees paid by pharmacies in Hungary and their correlation with quarterly incomes from reimbursed drugs, 2009
- Official wholesale markups for reimbursed drugs in Hungary, 2009
- Official retail markups for reimbursed drugs in Hungary, 2009
- Official wholesale and retail margins for Rx medicines in Slovakia, 2009
- Comparison between July 2009 and October 2009 reimbursement lists in Slovakia, in terms of patient co-payment (%)
- Comparison between July 2009 and October 2009 reimbursement lists in Slovakia, in terms of patient co-payment (€)
- Official wholesale and retail margins for Rx drugs in Bulgaria, 2009
- AstraZeneca sales in selected CEE countries, 2008
- AstraZeneca selected best selling generic and innovative drugs in Russia (€‘000), retail, hospital and DLO, 2008 and H1 2009
- AstraZeneca product pipeline development and clinical trials carried out in the CEE region, October 2009
- Bayer sales in selected CEE countries, 2008
- Bayer selected best selling generic and innovative drugs in Russia (€‘000), retail, hospital and DLO, 2008 and H1 2009
- Patent expiry date of selected Bayer key original products in European Union countries, 2009
- Bayer product pipeline development and clinical trials carried out in the CEE region, October 2009
- GSK sales in selected CEE countries, 2008
- GSK selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
- Patent expiry date of selected GlaxoSmithKline key original products in European Union countries, 2009
- Selected GSK clinical trials carried out in CEE countries, October 2009
- Novartis sales in selected CEE countries, 2008
- Novartis selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
- Patent expiry date of selected Novartis key original products on major European markets, 2009
- Novartis product pipeline development and clinical trials carried out in the CEE region, October 2009
- Pfizer sales in selected CEE countries, 2008
- Selected Pfizer clinical trials carried out in CEE countries, October 2009
- Roche sales in selected CEE countries, 2008
- Data exclusivity of selected Roche key original products in European Union countries, 2009
- Roche product pipeline development and clinical trials carried out in the CEE region, October 2009
- Sanofi-Aventis sales in selected CEE countries, 2008
- Sanofi-Aventis selected best selling drugs in Russia, 2008
- Patent expiry date of selected Sanofi-Aventis key original products in CEE countries, 2009
- Sanofi-Aventis product pipeline development and clinical trials carried out in the CEE region, July 2009
- Servier sales in selected CEE countries, 2008
- Servier selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
- Financial results of Balkanpharma member companies (BGN ‘000), 2007 and 2008
- Selected drugs launched by Antibiotice in Romania, 2009
- Dr. Reddy’s best selling products in Russia ($ m), 2006-2008
- Dr. Reddy’s clinical trials carried out worldwide, March 2009
- Drugs launched by Egis in Hungary, H1 2009
- Generic and innovative drugs launched by Gedeon Richter in selected CEE countries analysed, 2008
- Selected Gedeon Richter clinical trials, September 2009
- Krka best selling drugs in the CEE countries analysed, H1 2009
- Krka’s selected marketing authorisations gained via centralised procedure in the EU, 2009
- Pharmstandard best selling generic and innovative drugs in Russia (RUB m), H1 2009
- Pharmstandard innovative drugs brands, H1 2009
- Teva innovative drug brands and patent expiry date, 2009
- Teva generic drug brands in selected CEE countries, 2008
- Teva clinical trials, September 2009
- Zentiva top best selling brands (CZK m), 2008
- Zentiva best selling generic drugs, new drugs launched and new marketing authorisations received on selected CEE markets, 2008
- Top 10 leading companies on the Russian retail pharmaceutical market, by sales value, 2008
- Top 10 leading companies on the Russian hospital market, by sales value, 2008
- Top 10 leading companies on the Polish pharmaceutical market, by sales value, 2008
- Selected leading innovative companies on the Czech pharmaceutical market, 2008
- Top 10 leading companies on the Romanian pharmaceutical market, by sales value, 2008
- Top 10 leading companies on the Hungarian pharmaceutical market, by sales value, 2008
- Top 10 leading companies on the Romanian pharmaceutical market, by sales value, H1 2009
- Top 10 leading foreign generic companies on the Ukrainian pharmaceutical market, by sales value, 2008
- Top five leading innovative companies on the Ukrainian pharmaceutical market, by sales value, 2008
- Top five leading companies on the Bulgarian pharmaceutical market, by sales volume, 2008
description |
table of contents |
table of graphs and tables |
leaflet |
free article |
request more info
| |
|
